Last updated on September 2017

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas


Brief description of study

To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.

Clinical Study Identifier: NCT02763254

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Elizabeth Budde, MD

City of Hope
Duarte, CA United States
  Connect »

Catherine Bollard, MD

Children's National Medical Center
Washington, D.C., United States
  Connect »

Richard Ambinder, MD

John Hopkins
Baltimore, MD United States
  Connect »

Jeffrey Barnes, MD

Massachusetts General
Boston, MA United States
  Connect »

Yi Lin, MD

Mayo Clinic
Rochester, MN United States
  Connect »

Jia Ruan, MD

New York-Presbyterian/Weill Cornell
New York, NY United States
  Connect »

Jing-Zhou Hou, MD

Univ of Pittsburgh - Hillman Cancer Center
Pittsburgh, PA United States
  Connect »

Helen Heslop, MD

Baylor College of Medicine
Houston, TX United States
  Connect »

Yasushiro Oki, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »